Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 4/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19065194 | 1.00 | KDM5A (0.42) | KDM5APAK1HTTWNT3AKCNH2 | |
| Trifluoroacetic Acid SCHEMBL31181694 | 0.95 | KDM5A (0.41) | KDM5APAK1HTTWNT3AZAP70 | |
| Trifluoroacetic Acid SCHEMBL19065586 | 0.95 | KDM5A (0.41) | KDM5APAK1HTTWNT3AZAP70 | |
| SCHEMBL19065357 | 0.86 | CYP3A4 (0.38) | KDM5AKCNH2ADORA2AADORA2BADORA1 | |
| SCHEMBL19117141 | 0.84 | KCNH2 (0.36) | KDM5AHTTKCNH2ADORA2AADORA2B | |
| Trifluoroacetic Acid SCHEMBL19065504 | 0.83 | KDM5A (0.36) | KDM5AHTTKCNH2ADORA2AADORA2B | |
| Trifluoroacetic Acid SCHEMBL29675562 | 0.83 | KDM5A (0.36) | KDM5AHTTKCNH2ADORA2AADORA2B | |
| Trifluoroacetic Acid SCHEMBL23087051 | 0.83 | PRCP (0.37) | KDM5AHTT | |
| SCHEMBL29688308 | 0.82 | MKNK1 (0.37) | KDM5AKCNH2ALK | |
| SCHEMBL19065447 | 0.82 | MKNK1 (0.37) | KDM5AKCNH2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | KDM5A 2501/4885PAK1 211/4885HTT 2012/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | KDM5A 2501/4885PAK1 211/4885HTT 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.